Brind.

FDA granted tentative approval for Olaparib tablets, manufactured by Natco Pharma, which are bioequivalent to Lynparza.

1 report, 1 independent Updated Jul 20

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Natco Pharma FDA

Keep exploring

The entities involved

Natco Pharma
Indian pharmaceutical company
- Natco Pharma launched a generic drug in the US market.Mon 14:49
FDA
- Cardiff Oncology and Nerviano Medical Sciences are seeking FDA regulatory review for Phase 3 trials and managing a licensing dispute over onvansertib.23:18
- Policymakers are considering ways to influence the drug market, including potential changes to patent rights and the FDA approval process.22:15

Related events

Arise is seeking FDA approval for a drug as of October 7, 2026.Oct 7
Eli Lilly and AstraZeneca are involved in drug development and market competition, with the FDA issuing approvals and legal actions involving both companies.Oct 7

Coverage

Newest first; wire copies grouped

Jul 20indiatimes.com